Published in Eur Radiol on October 01, 2013
Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed (2016) 0.83
Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. Eur Radiol (2015) 0.78
Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. J Cancer Res Clin Oncol (2017) 0.77
Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. Eur Radiol (2016) 0.77
Evaluation of a Simplified Intravoxel Incoherent Motion (IVIM) Analysis of Diffusion-Weighted Imaging for Prediction of Tumor Size Changes and Imaging Response in Breast Cancer Liver Metastases Undergoing Radioembolization: A Retrospective Single Center Analysis. Medicine (Baltimore) (2016) 0.76
Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma. Onco Targets Ther (2016) 0.75
The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases. Onco Targets Ther (2016) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
A 5-decade analysis of 13,715 carcinoid tumors. Cancer (2003) 12.78
MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology (1986) 11.58
Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology (1988) 8.08
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci (2004) 4.13
Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol (2011) 2.33
Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer (2001) 2.32
Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology (1999) 2.19
Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging (2010) 1.96
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol (2008) 1.84
Intravoxel incoherent motion perfusion MR imaging: a wake-up call. Radiology (2008) 1.78
Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology (2008) 1.73
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer (2008) 1.67
The capillary network: a link between IVIM and classical perfusion. Magn Reson Med (1992) 1.65
Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer (2004) 1.62
Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol (2007) 1.60
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol (2009) 1.52
Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases. Eur Radiol (2012) 1.51
An in vivo verification of the intravoxel incoherent motion effect in diffusion-weighted imaging of the abdomen. Magn Reson Med (2010) 1.48
Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging (2008) 1.44
Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology (2008) 1.41
In vivo MR measurements of regional arterial and venous blood volume fractions in intact rat brain. Magn Reson Med (2000) 1.37
Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology (2010) 1.36
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol (2010) 1.36
Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging (2011) 1.34
Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging (2012) 1.33
Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. Eur Radiol (2006) 1.32
Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol (2009) 1.29
Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging (2012) 1.28
The frequency of gastrointestinal endocrine tumours in a well-defined population--Northern Ireland 1970-1985. Q J Med (1989) 1.25
Evaluation of hepatic lesions and hepatic parenchyma using diffusion-weighted echo-planar MR with three values of gradient b-factor. J Magn Reson Imaging (2006) 1.16
Carcinoid tumors of the gastrointestinal tract: a 44-year experience. South Med J (1989) 1.04
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin Cancer Res (2009) 1.02
Influence of perfusion on hepatic MR diffusion measurement. NMR Biomed (2006) 1.01
Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: effect of DWI techniques and calculation methods. J Magn Reson Imaging (2012) 1.00
Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur J Cancer (2012) 0.99
Reproductibility of apparent diffusion coefficients measurements in diffusion-weighted MRI of the abdomen with different b values. Eur J Radiol (2011) 0.99
Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology (2012) 0.98
In vitro and in vivo repeatability of abdominal diffusion-weighted MRI. Br J Radiol (2012) 0.98
Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol (2008) 0.90
Intravoxel incoherent motion model-based liver lesion characterisation from three b-value diffusion-weighted MRI. Eur Radiol (2013) 0.90
Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci (2009) 0.87
Interstitial fluid pressure correlates with intravoxel incoherent motion imaging metrics in a mouse mammary carcinoma model. NMR Biomed (2011) 0.86
Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol (2011) 0.84
90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med (2012) 0.83
Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. Neuroendocrinology (2012) 0.81
Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol (2011) 0.80
Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol (2013) 0.75
The importance of Tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. Clin Nucl Med (2012) 0.75
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet (2007) 5.63
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol (2005) 4.35
Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol (2010) 3.46
Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology (2006) 3.40
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology (2011) 3.26
1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging (2004) 2.47
Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients: a prospective study with 115 examinations. Circulation (2006) 2.25
Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology (2005) 2.16
Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol (2010) 1.98
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol (2013) 1.95
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology (2012) 1.94
Safety of brain 3-T MR imaging with transmit-receive head coil in patients with cardiac pacemakers: pilot prospective study with 51 examinations. Radiology (2008) 1.91
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Magnetic resonance imaging at 1.5-T in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol (2009) 1.87
First-pass and steady-state MR angiography of thoracic vasculature in children and adolescents. JACC Cardiovasc Imaging (2010) 1.74
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med (2011) 1.69
Sensitivity encoding for diffusion-weighted MR imaging at 3.0 T: intraindividual comparative study. Radiology (2005) 1.67
Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study. AJNR Am J Neuroradiol (2003) 1.66
Low-field magnetic resonance imaging: increased safety for pacemaker patients? Europace (2010) 1.57
Endovascular treatment of epistaxis: indications, management, and outcome. Cardiovasc Intervent Radiol (2011) 1.55
Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience. Radiology (2010) 1.54
Radium-223 in prostate cancer. N Engl J Med (2013) 1.53
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 1.52
False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer (2007) 1.47
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol (2003) 1.46
Abdomen: diffusion-weighted MR imaging with pulse-triggered single-shot sequences. Radiology (2002) 1.45
Effect of B1 inhomogeneity on breast MR imaging at 3.0 T. Radiology (2007) 1.45
Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy. Thromb Haemost (2008) 1.44
Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2014) 1.43
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41
Coronary MR angiography at 3.0 T versus that at 1.5 T: initial results in patients suspected of having coronary artery disease. Radiology (2005) 1.35
Evaluating the predictability of conformational switching in RNA. Bioinformatics (2004) 1.30
Cerebral arteriovenous malformation: Spetzler-Martin classification at subsecond-temporal-resolution four-dimensional MR angiography compared with that at DSA. Radiology (2007) 1.30
Clinical advantages of 3.0 T MRI over 1.5 T. Eur J Radiol (2007) 1.29
Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol (2007) 1.23
Whole-body high-field-strength (3.0-T) MR Imaging in Clinical Practice. Part I. Technical considerations and clinical applications. Radiology (2008) 1.21
Flow volume and shunt quantification in pediatric congenital heart disease by real-time magnetic resonance velocity mapping: a validation study. Circulation (2004) 1.20
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol (2003) 1.19
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
Evaluation of cumulative effects of MR imaging on pacemaker systems at 1.5 Tesla. Pacing Clin Electrophysiol (2009) 1.13
Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology (2009) 1.12
Randomly segmented central k-space ordering in high-spatial-resolution contrast-enhanced MR angiography of the supraaortic arteries: initial experience. Radiology (2002) 1.12
Acute and subacute ischemic stroke at high-field-strength (3.0-T) diffusion-weighted MR imaging: intraindividual comparative study. Radiology (2004) 1.11
Intracranial arteriovenous malformation: time-resolved contrast-enhanced MR angiography with combination of parallel imaging, keyhole acquisition, and k-space sampling techniques at 1.5 T. Radiology (2008) 1.10
131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med (2010) 1.10
Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol (2008) 1.10
Rapid left-to-right shunt quantification in children by phase-contrast magnetic resonance imaging combined with sensitivity encoding (SENSE). Circulation (2003) 1.10
Looking beyond the lumen to predict cerebrovascular events: "the road less travelled by". Stroke (2006) 1.08
Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. Am J Psychiatry (2003) 1.07
4D time-resolved MR angiography with keyhole (4D-TRAK): more than 60 times accelerated MRA using a combination of CENTRA, keyhole, and SENSE at 3.0T. J Magn Reson Imaging (2008) 1.07
Dual-source parallel RF transmission for clinical MR imaging of the spine at 3.0 T: intraindividual comparison with conventional single-source transmission. Radiology (2010) 1.06
Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med (2010) 1.06
Dual-source radiofrequency transmission with patient-adaptive local radiofrequency shimming for 3.0-T cardiac MR imaging: initial experience. Radiology (2012) 1.05
Resting-state perfusion in nonmedicated schizophrenic patients: a continuous arterial spin-labeling 3.0-T MR study. Radiology (2010) 1.05
Fixed drug eruption induced by an iodinated non-ionic X-ray contrast medium: a practical approach to identify the causative agent and to prevent its recurrence. Eur Radiol (2006) 1.04
Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol (2008) 1.04
DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol (2010) 1.04
Diffusion-weighted magnetic resonance imaging of the pancreas: diagnostic benefit from an intravoxel incoherent motion model-based 3 b-value analysis. Invest Radiol (2014) 1.01
High-resolution myocardial stress perfusion at 3 T in patients with suspected coronary artery disease. Eur Radiol (2007) 1.01
The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med (2010) 1.01
Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord (2010) 1.00
Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina (2015) 1.00